Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86,412 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
Ahmed KA, Abuodeh YA, Echevarria MI, Arrington JA, Stallworth DG, Hogue C, Naghavi AO, Kim S, Kim Y, Patel BG, Sarangkasiri S, Johnstone PA, Sahebjam S, Khushalani NI, Forsyth PA, Harrison LB, Yu M, Etame AB, Caudell JJ. Ahmed KA, et al. Among authors: kim s, kim y. Ann Oncol. 2016 Dec;27(12):2288-2294. doi: 10.1093/annonc/mdw417. Epub 2016 Sep 15. Ann Oncol. 2016. PMID: 27637745 Free PMC article.
Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study.
Ahmed KA, Kim Y, Arrington JA, Kim S, DeJesus M, Soyano AE, Armaghani AJ, Costa RLB, Khong HT, Loftus LS, Rosa M, Caudell JJ, Diaz R, Robinson TJ, Etame AB, Tran ND, Sahebjam S, Soliman HH, Czerniecki BJ, Forsyth PA, Yu HM, Han HS. Ahmed KA, et al. Among authors: kim s, kim y. Adv Radiat Oncol. 2021 Sep 11;6(6):100798. doi: 10.1016/j.adro.2021.100798. eCollection 2021 Nov-Dec. Adv Radiat Oncol. 2021. PMID: 34934864 Free PMC article.
Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): A single institutional retrospective review.
Wallace G, Kundalia R, Cao B, Kim Y, Smalley I, Forsyth P, Soyano A, Pina Y. Wallace G, et al. Among authors: kim y. Res Sq [Preprint]. 2023 Jun 8:rs.3.rs-2981094. doi: 10.21203/rs.3.rs-2981094/v1. Res Sq. 2023. Update in: Breast Cancer Res. 2024 Mar 29;26(1):55. doi: 10.1186/s13058-024-01789-7. PMID: 37333166 Free PMC article. Updated. Preprint.
Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
Dohm AE, Nakashima JY, Kalagotla H, Jiang SX, Tang JD, Bhandari M, Kim Y, Graham JA, Khushalani NI, Forsyth PA, Etame AB, Liu JK, Tran ND, Vogelbaum MA, Wuthrick EJ, Yu HM, Oliver DE, Ahmed KA. Dohm AE, et al. Among authors: kim y. Eur J Cancer. 2023 Oct;192:113287. doi: 10.1016/j.ejca.2023.113287. Epub 2023 Aug 7. Eur J Cancer. 2023. PMID: 37657227
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone.
Mills MN, Uno A, Li P, Liveringhouse C, Kim Y, Oliver DE, Perez BA, Creelan BC, Yu M, Forsyth PA, Pina Y, Ahmed KA. Mills MN, et al. Among authors: kim y. Clin Lung Cancer. 2024 Jul;25(5):417-423.e1. doi: 10.1016/j.cllc.2024.04.005. Epub 2024 Apr 10. Clin Lung Cancer. 2024. PMID: 38719648
Phase II Trial of Brain MRI Surveillance in Stage IV Breast Cancer.
Ahmed KA, Kim Y, Armaghani AJ, Arrington JA, Costa RL, Czerniecki BJ, Diaz R, Dowell RA, Extermann M, Forsyth PA, Lee KT, Loftus L, Mills MN, Phuoc VH, Rosa M, Soliman HH, Sam CS, Washington IR, Soyano AE, Han HS. Ahmed KA, et al. Among authors: kim y. Neuro Oncol. 2025 Jan 24:noaf018. doi: 10.1093/neuonc/noaf018. Online ahead of print. Neuro Oncol. 2025. PMID: 39851040
86,412 results
You have reached the last available page of results. Please see the User Guide for more information.